intravenous (IV) infusion for first three doses, subcutaneous (under skin) injection after
In Inflammatory Bowel Disease (IBD), it is used for moderate to severe Crohn's disease
Recommendations for Pregnancy
Insufficient trial data. Monoclonal antibodies may be transported across the placenta
Recommendations for Lactation
This medication is an interleukin-23 antagonist prescribed for the treatment of moderate to severe Crohn's disease in adults.
Indicated for pediatric use
Not indicated for pediatric use
Most common side effects
It may increase risk of infections including upper respiratory or urinary tract infections. Other side effects may include injection site reactions, abdominal pain, headache, and joint pains. Liver injury has been reported (liver enzymes and bilirubin levels should be monitored).
Patients should be evaluated for tuberculosis (TB) prior to starting this medication, and should not be given Skyrizi® if there is active TB. If there is a hypersensitivity reaction or anaphylaxis occurs, discontinue medication and initiate appropriate therapy immediately. Avoid use of live vaccines
Scroll right by clicking & dragging with your cursor or swiping with your finger.